Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in schizophrenia switching from antipsychotics
NCT05628103Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Dec 2022; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05628103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628103.